ASH 2020 Clinical Roundup

News Articles

(DocWire News) Dec 9, 2020 - Ajai Chari, MD, PhD, of Mount Sinai Medical Center in New York, NY, discusses findings from a phase I study of the novel agent talquetamab, a first-in-class bispecific antibody that binds to GPRC5D and CD3, for the treatment of relapsed/refractory multiple myeloma.
(OBR) Dec 8, 2020 - The STAMP inhibitor asciminib appears safe and effective as third-line treatment for patients with chronic myeloid leukemia (CML) in chronic phase, according to findings from the phase 3 ASCEMBL trial. The results, which were presented as part of a late breaking abstract session at the annual meeting of the...
(OBR) Dec 8, 2020 - Using whole genome sequencing, researchers have traced the genetic origins of myeloproliferative neoplasms to early childhood, and in some cases all the way back to the time in utero. The findings, which were presented during the late breaking abstract session at the annual meeting of the American Society of...
(OBR) Dec 7, 2020 - Single-agent mosunetuzumab appeared effective and well tolerated as first-line treatment for elderly and unfit patients with diffuse large B-cell lymphoma (DLBCL) in an early-phase trial, according to findings presented at the annual meeting of the American Society of Hematology. In the ongoing phase 1-2,...
(OBR) Dec 7, 2020 - Axicabtagene ciloleucel (axi-cel) appeared effective and well tolerated as first-line therapy for high-risk large B-cell lymphoma in the phase 2 ZUMA-12 study, which was presented at the annual meeting of the American Society of Hematology. ZUMA-12 is the first study to evaluate chimeric antigen receptor (CAR)...
View all ash conference coverage news
OBR Blog
By Lynne Lederman, PhD Enhancer Hijacking of BCL11B Defines a Subtype of Lineage Ambiguous Acute Leukemia (LBA3)... Read more
December 08, 2020
By Lynne Lederman, PhD Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone... Read more
December 07, 2020
Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms (Abstract 1) By Lynne Lederman,... Read more
December 06, 2020
By Lynne Lederman A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell... Read more
December 05, 2020